TPST241220C5000
- 0.00
- 0.000.00%
Tempest Therapeutics Newsroom
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
Tempest Therapeutics Reports Q3 2024 Financial Results
Tempest Therapeutics Is Maintained at Overweight by Piper Sandler
Tempest Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results.
Piper Sandler Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Cuts Target Price to $5
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)
Scotiabank Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)
Tempest Therapeutics: Promising Advancements and Strategic Partnerships Justify Buy Rating
Express News | Tempest Therapeutics Inc : Piper Sandler Cuts Target Price to $5 From $8
Tempest Therapeutics GAAP EPS of -$0.41 Misses by $0.05
Tempest Therapeutics | 10-Q: Q3 2024 Earnings Report
Tempest Therapeutics | 8-K: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | Tempest Therapeutics Q3 Net Income USD -10.556 Million Vs. IBES Estimate USD -9.33 Million
Press Release: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Tempest Therapeutics 3Q Loss/Shr 41c >TPST
Tempest Therapeutics 3Q Loss $10.6M >TPST
Express News | Tempest Therapeutics Inc - Phase 3 Study Expected to Start in Q1 2025
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma